CASP3 and breast cancer: Notably, Long et al. (2017) highlighted that hyperoside had less cytotoxicity to normal human mammary epithelial cells (MCF-10) with increased cell apoptosis and caspase-3 activity in paclitaxel-treated breast cancer cells (Sun et al., 2020).